Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antifungal Resistance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Antifungal Resistance. Displaying page 1 of 1.
    EudraCT Number: 2017-003571-56 Sponsor Protocol Number: APX001-201 Start Date*: 2018-12-17
    Sponsor Name:Amplyx Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non-Neutropenic Patients with Candidemia, with or without Invasive Candidiasis, Inclusive of Patients with Suspected Resistance ...
    Medical condition: Treatment of non-neutropenic subjects with candidemia – inclusive of those subjects with suspected or confirmed antifungal-resistant candidemia with or without invasive candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10060573 Candidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002644-23 Sponsor Protocol Number: MB_PDT_1 Start Date*: 2020-07-23
    Sponsor Name:Dept. of Dermatology, Zealand University Hospital, Roskilde
    Full Title: Photodynamic therapy of antifungal resistant dermatophytes
    Medical condition: Competent patients over 18 years old with mycological verified antifungal resistant dermatophytosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043870 Tinea infections HLT
    20.0 10021881 - Infections and infestations 10043868 Tinea cruris PT
    20.0 10021881 - Infections and infestations 10060889 Tinea infection PT
    21.1 10021881 - Infections and infestations 10043873 Tinea pedis PT
    20.0 10021881 - Infections and infestations 10049591 Tinea imbricata PT
    20.0 10021881 - Infections and infestations 10067197 Tinea manuum PT
    20.0 10021881 - Infections and infestations 10043872 Tinea NOS LLT
    20.1 10021881 - Infections and infestations 10043869 Tinea infection NOS LLT
    20.0 10021881 - Infections and infestations 10043867 Tinea corporis LLT
    20.0 10021881 - Infections and infestations 10043864 Tinea LLT
    20.0 10021881 - Infections and infestations 10053041 Tinea trichophytina cruris LLT
    20.0 10021881 - Infections and infestations 10073383 Tinea of hand LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000627-40 Sponsor Protocol Number: IA-DUET Start Date*: 2020-12-28
    Sponsor Name:Erasmus MC
    Full Title: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET)
    Medical condition: Invasive aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001386-33 Sponsor Protocol Number: APX001-202 Start Date*: 2019-08-20
    Sponsor Name:Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer, Inc.
    Full Title: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients with Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
    Medical condition: Treatment of patients with invasive mold infections (IMIs) caused by Aspergillus species (spp.) or rare molds
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10062642 Invasive mycosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000381-29 Sponsor Protocol Number: SCY-078-301 Start Date*: 2017-07-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI)
    Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-004211-30 Sponsor Protocol Number: 2005-23 Start Date*: 2005-10-17
    Sponsor Name:The Norwegian Radium Hospital
    Full Title: Penicillin G and an aminoglycoside versus meropenem as initial empiric antibiotic therapy in lymphoma and leukemia patients with febrile neutropenia
    Medical condition: Lymphoma and leukemia patients with febrile neutropenia
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003921-40 Sponsor Protocol Number: 2016IF002 Start Date*: 2017-07-21
    Sponsor Name:University Hospital of South Manchester NHS Foundation Trust
    Full Title: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis
    Medical condition: Chronic Pulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000154164 10003488 Aspergillosis LLT
    20.0 100000015649 10003493 Aspergillus fumigatus bronchopulmonary infection LLT
    20.0 100000154164 10003494 Aspergillus fumigatus infection LLT
    20.0 10021881 - Infections and infestations 10006473 Bronchopulmonary aspergillosis PT
    20.0 100000015649 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000386-32 Sponsor Protocol Number: F901318/0041 Start Date*: 2022-01-21
    Sponsor Name:F2G Ltd.
    Full Title: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with...
    Medical condition: invasive fungal infections due to Aspergillus spp.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001290-17 Sponsor Protocol Number: F901318/0032 Start Date*: 2018-03-30
    Sponsor Name:F2G Biotech GmbH (FN 483749 x)
    Full Title: An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in pat...
    Medical condition: invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004599-19 Sponsor Protocol Number: INTERFANT-06 Start Date*: 2005-11-24
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
    Medical condition: acute lymphoblastic leukemia (ALL) or biphenotypic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing) BE (Completed) FR (Ongoing) DE (Completed) GB (Completed) AT (Ongoing) PT (Ongoing) DK (Completed) IE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA